Showing 1 - 10 of 1,452
A country's pharmaceutical policy is unique, just like its culture. Japan is no exception. Japan has employed a unique dynamic price-control rule that updates regulated retail prices based on the previous period's transaction prices. At the same time, separation of prescribing and dispensing has...
Persistent link: https://www.econbiz.de/10014216804
We examine how R&D portfolios of drug pipelines affect pharmaceutical licensing, controlling firm size, diversity, and competitors in R&D and product markets. The data collected comprises 329 license-outs and 434 license-ins closed by 54 Japanese pharmaceutical companies between 1997 and 2007....
Persistent link: https://www.econbiz.de/10008808257
Persistent link: https://www.econbiz.de/10008653171
Persistent link: https://www.econbiz.de/10010430007
Persistent link: https://www.econbiz.de/10009672930
Pharmaceutical firms' use of secondary patents to extend periods of exclusivity generates concerns among policymakers worldwide. In response, some developing countries have introduced measures to curb the grant of these patents. While these measures have received considerable attention, there is...
Persistent link: https://www.econbiz.de/10012964387
Persistent link: https://www.econbiz.de/10012671490
Persistent link: https://www.econbiz.de/10011876356
Pharmaceutical firms' use of secondary patents to extend periods of exclusivity generates concerns among policymakers worldwide. In response, some developing countries have introduced measures to curb the grant of these patents. While these measures have received considerable attention, there is...
Persistent link: https://www.econbiz.de/10012455567
, Hoshi Pharmaceuticals, and a commodity history of its involvement in opium, quinine, and consumer medicines in both Japan …
Persistent link: https://www.econbiz.de/10012313840